Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
12.040USD
+0.150+1.26%
Close 07-29 16:00（ET）Quotes delayed by 15 min
316.06MMarket Cap
LossP/E TTM
More Details of Benitec Biopharma Inc Company
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Benitec Biopharma Inc Info
Ticker SymbolBNTC
Company nameBenitec Biopharma Inc
IPO dateJul 11, 2012
CEOBanks (Jerel A)
Number of employees19
Security typeOrdinary Share
Fiscal year-endJul 11
Address3940 Trust Way
CityHAYWARD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94545
Phone15107800819
Websitehttps://benitec.com/
Ticker SymbolBNTC
IPO dateJul 11, 2012
CEOBanks (Jerel A)
Company Executives of Benitec Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Benitec Biopharma Inc?
The top five shareholders of Benitec Biopharma Inc are: Ms. Megan Joan Boston
How many institutions hold shares of Benitec Biopharma Inc (BNTC)?
As of 2026Q1, 131 institutions hold shares of Benitec Biopharma Inc, with a combined market value of approximately 33.05M, accounting for 96.50% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5127649.00.